Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TPMT | P51580 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6736179 | 0.88 | HSD17B10 (0.55) | ACHEPKMKDM4EALDH1A1HPGD | |
| SCHEMBL14373029 | 0.84 | TSHR (0.49) | ACHEKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL10355686 | 0.83 | ACHE (0.57) | ACHEPKMKDM4EALDH1A1HPGD | |
| SCHEMBL7820121 | 0.82 | HSD17B10 (0.50) | ACHEPKMKDM4EALDH1A1HPGD | |
| SCHEMBL10920134 | 0.82 | KDM4E (0.55) | ACHEPKMKDM4EALDH1A1HPGD | |
| SCHEMBL14363157 | 0.81 | PKM (0.55) | ACHEPKMKDM4EALDH1A1HPGD | |
| SCHEMBL8554349 | 0.81 | MAPT (0.63) | PKMKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL10355688 | 0.81 | ACHE (0.59) | ACHEPKMKDM4EALDH1A1HPGD | |
| SCHEMBL1613893 | 0.81 | TPMT (0.68) | PKMKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL9191019 | 0.81 | KDM4E (0.53) | ACHEPKMKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354439-B2 | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20070238758-A1 | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion | OTSUKA PHARMACEUTICAL CO., LTD. | 2007-10-11 | — | — | US | disclosed |
| US-20070105911-A1 | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion | CHIHIRO MASATOSHI | 2007-05-10 | — | — | US | disclosed |
| EP-0207913-B1 | CATECHOL CARBOXAMIDES, PROCESS FOR THEIR PREPARATION, INTERMEDIATES AND A PHARMACEUTICAL PREPARATION | Astra Läkemedel Aktiebolag (SE) | 1990-10-31 | — | — | EP | disclosed |
| EP-0207913-A1 | Catechol carboxamides, process for their preparation, intermediates and a pharmaceutical preparation | Astra Läkemedel Aktiebolag (SE) | 1987-01-07 | — | — | EP | disclosed |
| WO-1986007591-A1 | CATECHOLCARBOXAMIDES, PROCESS FOR THEIR PREPARATION, INTERMEDIATES AND A PHARMACEUTICAL PREPARATION | Astra Läkemedel Aktiebolag (SE) | 1986-12-31 | — | — | WO | disclosed |
| US-4530845-A | Substituted with a phenyl group in position 2 | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-07-23 | — | — | US | disclosed |
| EP-0047323-B1 | 1,4-NAPHTHOQUINONE DERIVATIVES AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-10 | — | — | EP | disclosed |
| US-4414226-A | 1,4-Naphtoquinone derivatives and their use in treating coccidiosis | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-08 | — | — | US | disclosed |
| EP-0047323-A1 | 1,4-NAPHTHOQUINONE DERIVATIVES AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238758-A1 | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion | IL2, IL1RN, SELL | ACHE 4454/4885PKM 3527/4885KDM4E 3406/4885 |
| US-20070105911-A1 | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion | IL2, IL1RN, SELL | ACHE 4462/4885PKM 3495/4885KDM4E 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.